1.96
0.02 (0.92%)
| Previous Close | 1.94 |
| Open | 1.99 |
| Volume | 16,398 |
| Avg. Volume (3M) | 153,159 |
| Market Cap | 50,754,400 |
| Price / Sales | 1.95 |
| Price / Book | 0.870 |
| 52 Weeks Range | |
| Earnings Date | 9 Aug 2024 - 13 Aug 2024 |
| Profit Margin | -85.75% |
| Operating Margin (TTM) | -748.92% |
| Diluted EPS (TTM) | -0.540 |
| Quarterly Revenue Growth (YOY) | -69.70% |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -11.46 M |
| Levered Free Cash Flow (TTM) | -8.70 M |
| Return on Assets (TTM) | -21.35% |
| Return on Equity (TTM) | -36.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ocuphire Pharma, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.17 |
|
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.11% |
| % Held by Institutions | 8.70% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |